The researchers looked at the role of a protein called ABCF1 in regulating sepsis progression.
Building on previous knowledge of ABCF1 as part of a family of proteins that plays a significant role in the immune system, the researchers analyzed ABCF1’s role in white blood cells during inflammation in a mouse model of sepsis.
“Sepsis triggers an uncontrolled chain-reaction of inflammation in the body, leading to tissue damage, organ failure and death,” said Hitesh Arora, co-lead study author. “We have discovered that the enzyme ABCF1 acts as a ‘switch’ at the molecular level that can stop this inflammatory chain-reaction and dampen the potential damage.”
This finding may lead to new treatments for chronic and acute inflammatory diseases, as well as autoimmune diseases.
“Our study may lead to therapies that overcome inflammatory and autoimmune disease such as rheumatoid arthritis, inflammatory bowel disease, Crohn’s disease and ulcerative colitis,” said senior author Wilfred Jefferies.
More articles on clinical leadership and infection control:
Only half of EMS workers confident in detecting sepsis, survey finds
6 patients infected with hep C at Los Angeles clinic, health officials say
CRISPR used to treat patient with dangerous blood disease, biotech company says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
